MorphoSys Reaches Second Clinical Milestone with OncoMed Pharmaceuticals
"This is our first clinical milestone in 2011 bringing the total number of clinical programs with partners to 16," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Additionally, the advancement of a second antibody program into clinical studies within the OncoMed alliance clearly demonstrates the success of this collaboration."
In June 2006, MorphoSys and US-based biopharmaceutical company OncoMed Pharmaceuticals announced the signing of a license agreement on the use of MorphoSys's HuCAL technology in the research and development of human therapeutic antibodies for the treatment of various cancers, including breast, lung, colon and prostate cancer, by targeting cancer stem cells. In June 2008, the collaboration was extended until the end of May 2010. The contract included an option for OncoMed to develop up to five HuCAL-derived therapeutic antibodies. OncoMed already has one HuCAL-based antibody, namely OMP-59R5, in clinical trials.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous